Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

1,573 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Clonally-Related CD5+ CLL/SLL and CD10+ high grade B-cell lymphoma suggests common neoplastic progenitor with branched disease evolution, with therapeutic implications.
Kumar P, Uppal M, Xiao W, Dogan A, Roshal M, Gao Q, Aypar U, Zhang Y, Arcila ME, Moung C, Yao J, Nafa K, Yu W, Syed MH, Park J, Kumar A, Ho C. Kumar P, et al. Among authors: dogan a. Leuk Lymphoma. 2020 Feb;61(2):460-464. doi: 10.1080/10428194.2019.1675876. Epub 2019 Oct 15. Leuk Lymphoma. 2020. PMID: 31612754 Free PMC article. No abstract available.
Immunophenotypic evidence for reactive polyclonal marrow plasmacytosis in multiple myeloma patients receiving lenalidomide maintenance.
Hassoun H, Roshal M, Sabari J, Nguyen J, Gao Q, Devlin SM, Landau H, Lendvai N, Chung DJ, Lesokhin AM, Korde N, Mailankody S, Dogan A, Giralt SA, Landgren CO. Hassoun H, et al. Among authors: dogan a. Leuk Lymphoma. 2017 Dec;58(12):2962-2965. doi: 10.1080/10428194.2017.1312382. Epub 2017 May 9. Leuk Lymphoma. 2017. PMID: 28482750 No abstract available.
Tumor suppressor CD99 is downregulated in plasma cell neoplasms lacking CCND1 translocation and distinguishes neoplastic from normal plasma cells and B-cell lymphomas with plasmacytic differentiation from primary plasma cell neoplasms.
Gao Q, Yellapantula V, Fenelus M, Pichardo J, Wang L, Landgren O, Dogan A, Roshal M. Gao Q, et al. Among authors: dogan a. Mod Pathol. 2018 Jun;31(6):881-889. doi: 10.1038/s41379-018-0011-0. Epub 2018 Feb 5. Mod Pathol. 2018. PMID: 29403080 Free PMC article.
Pilot trial of ibrutinib in patients with relapsed or refractory T-cell lymphoma.
Kumar A, Vardhana S, Moskowitz AJ, Porcu P, Dogan A, Dubovsky JA, Matasar MJ, Zhang Z, Younes A, Horwitz SM. Kumar A, et al. Among authors: dogan a. Blood Adv. 2018 Apr 24;2(8):871-876. doi: 10.1182/bloodadvances.2017011916. Blood Adv. 2018. PMID: 29669753 Free PMC article. Clinical Trial.
Integrated DNA/RNA targeted genomic profiling of diffuse large B-cell lymphoma using a clinical assay.
Intlekofer AM, Joffe E, Batlevi CL, Hilden P, He J, Seshan VE, Zelenetz AD, Palomba ML, Moskowitz CH, Portlock C, Straus DJ, Noy A, Horwitz SM, Gerecitano JF, Moskowitz A, Hamlin P, Matasar MJ, Kumar A, van den Brink MR, Knapp KM, Pichardo JD, Nahas MK, Trabucco SE, Mughal T, Copeland AR, Papaemmanuil E, Moarii M, Levine RL, Dogan A, Miller VA, Younes A. Intlekofer AM, et al. Among authors: dogan a. Blood Cancer J. 2018 Jun 12;8(6):60. doi: 10.1038/s41408-018-0089-0. Blood Cancer J. 2018. PMID: 29895903 Free PMC article.
Establishment of Immunoglobulin Heavy (IGH) Chain Clonality Testing by Next-Generation Sequencing for Routine Characterization of B-Cell and Plasma Cell Neoplasms.
Arcila ME, Yu W, Syed M, Kim H, Maciag L, Yao J, Ho C, Petrova K, Moung C, Salazar P, Rijo I, Baldi T, Zehir A, Landgren O, Park J, Roshal M, Dogan A, Nafa K. Arcila ME, et al. Among authors: dogan a. J Mol Diagn. 2019 Mar;21(2):330-342. doi: 10.1016/j.jmoldx.2018.10.008. Epub 2018 Dec 25. J Mol Diagn. 2019. PMID: 30590126 Free PMC article.
1,573 results